Stockscreener 앱 받기
12.86
1.98%
0.25
전일 마감가:
$12.61
열려 있는:
$12.77
하루 거래량:
70,975
Relative Volume:
0.38
시가총액:
$803.29M
수익:
-
순이익/손실:
$-41.43M
주가수익비율:
-16.28
EPS:
-0.79
순현금흐름:
$-39.97M
1주 성능:
+6.90%
1개월 성능:
+27.33%
6개월 성능:
+58.57%
1년 성능:
+5.07%
1일 변동 폭
$12.59
$12.97
1주일 범위
$10.96
$12.97
52주 변동 폭
$6.00
$20.50
Gh Research Plc Stock (GHRS) Company Profile
GHRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
12.95 | 749.30M | 0 | -41.43M | -39.97M | -0.79 |
|
ONC
Beone Medicines Ltd Adr
|
256.46 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.90 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2213 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.34 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
499.27 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-13 | 개시 | Guggenheim | Buy |
| 2025-03-07 | 개시 | RBC Capital Mkts | Outperform |
| 2025-02-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-08-16 | 개시 | H.C. Wainwright | Buy |
| 2022-06-16 | 개시 | ROTH Capital | Buy |
모두보기
Gh Research Plc 주식(GHRS)의 최신 뉴스
Cantor Fitzgerald Initiates Coverage of GH Research (GHRS) With Overweight Rating - Insider Monkey
GH Research (NASDAQ:GHRS) Now Covered by Cantor Fitzgerald - Defense World
GHRS Stock Coverage Initiated with Positive Outlook | GHRS Stock News - GuruFocus
cantor fitzgerald maintains overweight rating on gh research stock By Investing.com - Investing.com Canada
cantor fitzgerald maintains overweight rating on gh research stock - Investing.com
BNP Paribas Financial Markets Takes $44,000 Position in GH Research PLC (NASDAQ:GHRS) - Defense World
How To Trade (GHRS) - news.stocktradersdaily.com
Northern Trust Corp Has $286,000 Holdings in GH Research PLC (NASDAQ:GHRS) - Defense World
GH Research to Present at ASCP Meeting on Breakthrough Depression Treatment - TipRanks
(GHRS) Long Term Investment Analysis - news.stocktradersdaily.com
GH Research to Present at ASCP Meeting on Depression Treatments - TipRanks
GH Research PLC (NASDAQ:GHRS) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Beckley’s psychedelic reduces depression - BioWorld MedTech
GH Research (NASDAQ:GHRS) Upgraded at Cantor Fitzgerald - Defense World
GH Research (GHRS) Highlights Phase 2b Results at Clinical Confe - GuruFocus
GH Research (GHRS) Highlights Phase 2b Results at Clinical Conference | GHRS Stock News - GuruFocus
GH Research Showcases Promising Depression Treatment Data at ASCP Meeting - TipRanks
GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting - Yahoo
GH Research’s (GHRS) “Buy” Rating Reiterated at HC Wainwright - Defense World
Guggenheim Cuts GH Research (NASDAQ:GHRS) Price Target to $29.00 - Defense World
GH Research (GHRS) Price Target Lowered by Guggenheim | GHRS Sto - GuruFocus
GHRS Stock: HC Wainwright & Co. Reiterates Buy Rating | GHRS Sto - GuruFocus
GH Research: Promising Clinical Results and Strong Financial Position Justify Buy Rating - TipRanks
GH Research (GHRS) Price Target Lowered by Guggenheim | GHRS Stock News - GuruFocus
GH Research PLC Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
GHRS Reports Strong Financial Position with Increased Cash Holdi - GuruFocus
GH Research Reports Q1 2025 Financial Results Amidst Ongoing Challenges - TipRanks
GH Research PLC Reports Positive Phase 2b Trial Results for GH001 in Treatment-Resistant Depression and Financial Update for Q1 2025 - Nasdaq
GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates - Stock Titan
What Makes GH Research (GHRS) a New Buy Stock - Yahoo Finance
Where are the Opportunities in (GHRS) - news.stocktradersdaily.com
Hims & Hers Health (NYSE:HIMS) Shares Down 8.3% Following Insider Selling - American Banking and Market News
Legal & General Group Plc Sells 18,302 Shares of Guardant Health, Inc. (NASDAQ:GH) - Defense World
What Will GH Research PLC (NASDAQ: GHRS) Be Like In 2025 - Stocksregister
Psyence BioMed invests half a million into natural psychedelics operator PsyLabs - Mugglehead Magazine
(GHRS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
(GHRS) Proactive Strategies - news.stocktradersdaily.com
JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Guggenheim starts GH Research at Buy, sees long-term upside potential - Yahoo Finance
Guggenheim Initiates Coverage of GH Research (GHRS) with Buy Recommendation - Nasdaq
GH Research PLC (GHRS) Shares Rise Despite Market Challenges - The News Heater
How to Take Advantage of moves in (GHRS) - news.stocktradersdaily.com
GH Research (NASDAQ:GHRS) Earns Outperform Rating from Analysts at Royal Bank of Canada - Defense World
GH Research PLC (NASDAQ:GHRS) Receives $30.67 Consensus PT from Brokerages - Defense World
Q1 Earnings Forecast for GH Research Issued By HC Wainwright - Defense World
RBC Capital Initiates Coverage of GH Research (GHRS) with Outperform Recommendation - Nasdaq
FY2029 EPS Estimates for GH Research Lifted by HC Wainwright - Defense World
GH Research initiated with an Outperform at RBC Capital - TipRanks
GH Research PLC Reports 2024 Financial Results and Clinical Progress - TipRanks
H.C. Wainwright maintains $40 target on GH Research stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $40 target on GH Research stock - Investing.com
Gh Research Plc (GHRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.30%
3.35%
자본화:
|
볼륨(24시간):